“We rate TEVA 12-month price target of $18. We like Teva’s stock and believe that there is a lot of value to be unlocked, but that it will take time for new leadership to return the business to growth. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12- month price target of $18.”
According to TipRanks.com, Chen has 0 stars on 0-5 star ranking scale with an average return of -7.3% and a 41.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Paratek Pharmaceuticals, and Spero Therapeutics Inc.
Currently, the analyst consensus on Teva Pharma is Hold and the average price target is $19.92, representing a -5.7% downside.
In a report issued on May 3, Maxim Group also maintained a Hold rating on the stock.
The company has a one-year high of $33.82 and a one-year low of $10.85. Currently, Teva Pharma has an average volume of 11.34M.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which engages in development, production and marketing of drugs, generic drugs, over-the-counter drugs, active ingredients for the pharmaceutical industry (APIs) and therapeutic products. It operates through two segments: Generic Medicines and Specialty Medicines.
Read More on TEVA: